---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-170701"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:55:48.794292+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics prices $150M registered offering; net proceeds ~$144.7M

## Summary
- Offering of 5,540,000 shares at $23.50/share and 850,000 pre-funded warrants at $23.499 each.
- Net proceeds of ~$144.7M to fund R&D for MZE829 (AMKD) and MZE782 (PKU, CKD) and general corporate purposes.
- Expected to close April 23, 2026; Leerink Partners LLC is sole underwriter.
- Participants include Farallon, T. Rowe Price, Frazier Life Sciences, Janus Henderson, and others.
- Cash runway extended into 2029 based on current business plan.

## SEC filing metadata
- accession: 0001193125-26-170701
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526170701/0001193125-26-170701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526170701/d115741d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-170701
- JSON: https://secwatch.observer/filing/0001193125-26-170701.json
- Plain text: https://secwatch.observer/filing/0001193125-26-170701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.